{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:53:15Z","timestamp":1792666395773,"version":"4.5.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Two interventions to prevent severe respiratory syncytial virus (RSV) in infants were approved in 2023\u2014a bivalent prenatal RSV prefusion F protein\u2013based (RSVpreF) vaccine and an infant monoclonal antibody (nirsevimab). Understanding their uptake and clinical outcomes is essential for public health planning.<\/jats:p><\/jats:sec>Objective<\/jats:title>To describe uptake of the prenatal RSVpreF vaccine and infant nirsevimab.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study was conducted at a single academic center among 647 pregnant individuals eligible for RSVpreF vaccination (32-36 weeks\u2019 gestation between October 15, 2023, and January 31, 2024) and infants eligible for nirsevimab (no prenatal RSVpreF vaccination &amp;gt;14 days before delivery).<\/jats:p><\/jats:sec>Exposure<\/jats:title>Pregnancy or birth during the 2023-2024 RSV season.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>RSVpreF vaccination among eligible pregnant individuals and nirsevimab administration prior to hospital discharge among eligible infants.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 647 eligible pregnant individuals (mean [SD] age, 34.6 [6.2] years; 355 nulliparous [54.9%]; 558 privately insured [86.2%]), 414 (64.0%) received the RSVpreF vaccine. Factors associated with higher RSVpreF uptake included older birthing parent age (adjusted odds ratio [AOR], 1.09; 95% CI, 1.05-1.12), nulliparity (AOR, 1.84; 95% CI, 1.31-2.60), private insurance (AOR, 2.19; 95% CI, 1.27-3.80), non-Hispanic ethnicity (AOR, 2.36; 95% CI 1.57-3.55; reference: Hispanic), receipt of any COVID-19 vaccine (AOR, 7.12; 95% CI, 3.91-13.70), 2023-2024 formula COVID-19 booster vaccine (AOR, 5.62; 95% CI, 3.80-8.48), influenza vaccine (AOR, 8.14; 95% CI, 5.38-12.50), or tetanus-diphtheria-pertussis vaccine (AOR, 6.86; 95% CI, 3.79-13.10). Factors associated with lower RSVpreF uptake included non-English language preference (AOR, 0.24; 95% CI, 0.10-0.52), Black race (AOR, 0.30; 95% CI, 0.16-0.57; reference: Asian), other or unknown race (AOR, 0.48; 95% CI, 0.30-0.76), and multiple gestation (AOR, 0.27; 95% CI, 0.07-0.88). Nirsevimab was administered to 183 of 261 eligible infants (70.1%) prior to hospital discharge. Among those who did not receive RSVpreF or standard prenatal vaccines, 40.4% of their neonates (19 of 47) received nirsevimab; among those who declined infant hepatitis B vaccination, 34.0% of their neonates (17 of 50) received nirsevimab. Respiratory syncytial virus coverage exceeded 80% during all months of the study period except October 2023, the first month during which prenatal RSV vaccination and infant nirsevimab were available. Preterm delivery occurred in 35 of 414 RSVpreF-vaccinated individuals (8.5%) and 43 of 233 unvaccinated individuals (18.5%). In a nested case-control analysis with preterm birth as the outcome, there was no significant association between RSVpreF vaccination and preterm birth (AOR, 1.03; 95% CI, 0.55-1.93).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, uptake of the RSVpreF vaccine and infant nirsevimab was high. Nirsevimab uptake was high even among individuals who did not receive routine prenatal or infant vaccines. There was no significant association between RSVpreF vaccination and preterm birth. This study suggests that an RSV prevention strategy that included both prenatal vaccination and infant monoclonal antibody administration had high uptake and reassuring perinatal outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.60735","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:01:03Z","timestamp":1739980863000},"page":"e2460735","source":"Crossref","is-referenced-by-count":40,"title":["Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates"],"prefix":"10.1001","volume":"8","author":[{"given":"Christine A.","family":"Blauvelt","sequence":"first","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Zeme","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Natarajan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Epstein","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Roh","sequence":"additional","affiliation":[{"name":"Institute for Global Health Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amayrani","family":"Morales","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Bourdoud","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie J.","family":"Flaherman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Prahl","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Gaw","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"11","key":"zoi241691r1","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJMe2401072","article-title":"Maternal RSV vaccine\u2014weighing benefits and risks.","volume":"390","author":"Rasmussen","year":"2024","journal-title":"N Engl J Med"},{"key":"zoi241691r2","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1093\/infdis\/jiac155","article-title":"Respiratory syncytial virus burden and healthcare utilization in United States infants <1 year of age: study of nationally representative databases, 2011-2019.","volume":"226","author":"Suh","year":"2022","journal-title":"J Infect Dis"},{"key":"zoi241691r3","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1093\/infdis\/jiac120","article-title":"Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the National (Nationwide) Inpatient Sample.","volume":"226","author":"Suh","year":"2022","journal-title":"J Infect Dis"},{"issue":"10098","key":"zoi241691r4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study.","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"issue":"16","key":"zoi241691r5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants.","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi241691r6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants.","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"issue":"34","key":"zoi241691r8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"zoi241691r9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants.","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi241691r10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","article-title":"RSV prefusion F protein\u2013based maternal vaccine\u2014preterm birth and other outcomes.","volume":"390","author":"Dieussaert","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi241691r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19268","article-title":"Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes.","volume":"7","author":"Son","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi241691r16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/aje\/kws412","article-title":"The table 2 fallacy: presenting and interpreting confounder and modifier coefficients.","volume":"177","author":"Westreich","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"6","key":"zoi241691r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16077","article-title":"Pediatric respiratory syncytial virus hospitalizations, 2017-2023.","volume":"7","author":"Fitzpatrick","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"29","key":"zoi241691r20","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.vaccine.2023.05.047","article-title":"Vaccine hesitancy in pregnant women: a narrative review.","volume":"41","author":"Mitchell","year":"2023","journal-title":"Vaccine"},{"issue":"3","key":"zoi241691r21","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab433","article-title":"Sources of vaccine hesitancy: pregnancy, infertility, minority concerns, and general skepticism.","volume":"9","author":"Hsu","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"zoi241691r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.24109","article-title":"Perinatal outcomes among patients with sepsis during pregnancy.","volume":"4","author":"Blauvelt","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zoi241691r25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.acap.2019.04.003","article-title":"Refusal of vitamin K by parents of newborns: a qualitative study.","volume":"19","author":"Loyal","year":"2019","journal-title":"Acad Pediatr"},{"issue":"4","key":"zoi241691r26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.acap.2016.10.012","article-title":"Refusal of vitamin K by parents of newborns: a survey of the Better Outcomes Through Research for Newborns Network.","volume":"17","author":"Loyal","year":"2017","journal-title":"Acad Pediatr"},{"issue":"17","key":"zoi241691r27","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1016\/j.vaccine.2023.03.039","article-title":"First hepatitis B vaccine uptake in neonates prior to and during the COVID-19 pandemic.","volume":"41","author":"Dugovich","year":"2023","journal-title":"Vaccine"},{"key":"zoi241691r7","unstructured":"US Food and Drug Administration. FDA approves new drug to prevent RSV in babies and toddlers. July 17, 2023. Accessed July 25, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-prevent-rsv-babies-and-toddlers"},{"key":"zoi241691r11","unstructured":"US Food and Drug Administration. FDA approves first vaccine for pregnant individuals to prevent RSV in infants. August 21, 2023. Accessed July 25, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants"},{"key":"zoi241691r12","unstructured":"Centers for Disease Control and Prevention. Respiratory syncytial virus (RSV) vaccine safety. October 3, 2024. Accessed October 10, 2024. https:\/\/www.cdc.gov\/vaccine-safety\/vaccines\/rsv.html"},{"key":"zoi241691r14","unstructured":"STROBE: Strengthening the Reporting of Observational Studies in Epidemiology. What is STROBE? Accessed April 26, 2024. https:\/\/www.strobe-statement.org\/"},{"key":"zoi241691r15","unstructured":"California Immunization Coalition. California Immunization Registry. Accessed August 1, 2024. https:\/\/www.immunizeca.org\/ca-cair-registry\/"},{"key":"zoi241691r17","unstructured":"Centers for Disease Control and Prevention. RSVVaxView. June 21, 2024. Accessed August 2, 2024. https:\/\/www.cdc.gov\/rsvvaxview"},{"key":"zoi241691r19","unstructured":"Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV): vaccines for older adults. July 3, 2024. Accessed July 25, 2024. https:\/\/www.cdc.gov\/rsv\/vaccines\/older-adults.html"},{"key":"zoi241691r22","unstructured":"City and County of San Francisco. Percentage of preterm births. Accessed July 25, 2024. https:\/\/www.sf.gov\/data\/percentage-preterm-births"},{"key":"zoi241691r24","unstructured":"Centers for Disease Control and Prevention. Limited availability of nirsevimab in the United States\u2014interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023-2024 respiratory virus season. October 23, 2023. Accessed July 25, 2024. https:\/\/emergency.cdc.gov\/han\/2023\/han00499.asp"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2830382\/blauvelt_2025_oi_241691_1739220980.90752.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:01:08Z","timestamp":1739980868000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2830382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.60735","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}